AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Apr 5, 2021
31637_dirs_2021-04-05_ae203285-7bae-4d42-afe5-0ebcb12016b7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-04-01
Reporting Person: Watts Ryan J. (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-09 | Common Stock | G | 40000 | $0.00 | Disposed | 2265742 | Indirect |
| 2021-04-01 | Common Stock | S | 5232 | $55.521 | Disposed | 2260510 | Indirect |
| 2021-04-01 | Common Stock | S | 8516 | $56.876 | Disposed | 2251994 | Indirect |
| 2021-04-01 | Common Stock | S | 4586 | $57.314 | Disposed | 2247408 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 156691 | Direct |
Footnotes
F1: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F2: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F3: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.245 to $56.235 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.32 to $57.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.038 to $58.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6: Includes 156,691 restricted stock units.